Physician profile
Jared Scherer
NPI 1235761107
$2,247.20
in general payments reported to CMS, 2019-2025
23 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $554 · 2022: $465 · 2023: $483 · 2024: $568 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $760.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $571.04 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $231.77 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $109.20 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $84.02 | 2021-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $49.64 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.73 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.31 | 2021-2024 | |
| Amarin Pharma, INC. | $43.49 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.46 | 2021-2024 | Xifaxan |
| Pfizer INC. | $33.53 | 2024-2025 | |
| Ethicon US, LLC | $32.73 | 2023 | Vicryl |
| Janssen Biotech, INC. | $29.10 | 2024 | Tremfya |
| Actelion Pharmaceuticals US, INC. | $24.87 | 2024 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $24.70 | 2025 | Spravato |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $24.22 | 2021 | |
| Organon LLC | $18.74 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $18.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.74 | 2025 | |
| Phathom Pharmaceuticals, INC. | $12.69 | 2025 | Voquezna |
| Dexcom, INC. | $11.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.31 | 2021 | |
| Abbott Laboratories | $7.23 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Scherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.